Los inhibidores SGLT2: una mirada al futuro del tratamiento de la insuficiencia cardiaca / Sodium-glucose cotransporter 2 inhibitors for the management of heart failure
Rev. méd. Chile
; 150(12): 1647-1654, dic. 2022. ilus, tab
Article
in Spanish
| LILACS
| ID: biblio-1515395
Responsible library:
CL1.1
ABSTRACT
Heart failure (HF) is a global health problem. There is a strong association h between HF and type 2 diabetes mellitus (DM2), with an increasing prevalence of patients having both conditions concomitantly. Sodium-glucose cotransporter 2 inhibitors (ISGLT2) significantly reduce cardiovascular events, including cardiovascular death. In this article we will focus on the current evidence about the effectiveness of these medications in adults with heart failure with reduced or preserved ejection fraction.
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Target 3.8 Achieve universal access to health
/
Cardiovascular Disease
/
Endocrine System Diseases
/
Other circulatory Diseases
Database:
LILACS
Main subject:
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2 Inhibitors
/
Heart Failure
Limits:
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2022
Document type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Clínica Alemana de Santiago/CL